Dolutegravir/Rilpivirine: A Review in HIV-1 Infection
- 209 Downloads
Dolutegravir/rilpivirine (Juluca®) is the first two-drug single-tablet regimen (STR) to be approved for the treatment of HIV-1 infection in adults. The fixed-dose STR combines the integrase strand transfer inhibitor dolutegravir with the non-nucleoside reverse transcriptase inhibitor rilpivirine. In two phase III non-inferiority trials (SWORD-1 and SWORD-2) in treatment-experienced patients already virologically suppressed on their current antiretroviral (ART) regimen, switching to once-daily dolutegravir plus rilpivirine maintained virological suppression over 48 weeks. Switching to a two-drug regimen of dolutegravir plus rilpivirine was also associated with high rates of virological suppression in real-world observational studies. Switching to once-daily dolutegravir plus rilpivirine was generally well tolerated and associated with more favourable renal and bone parameters than remaining on the current ART regimen. Longer-term, dolutegravir plus rilpivirine demonstrated durable maintenance of virological suppression and remained generally well tolerated for up to 100 weeks. Thus, dolutegravir/rilpivirine provides a convenient alternative treatment option for some adults with HIV-1 infection and no history of virological failure who are already virologically suppressed on (and wish to switch from) their current ART regimen.
During the peer review process, the manufacturer of dolutegravir/rilpivirine was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
Hannah Blair is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 2.European AIDS Clinical Society. Guidelines version 9.0; 2017. http://eacsociety.org. Accessed 29 Oct 2018.
- 3.US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2018. https://adisinfo.nih.gov/guidelines. Accessed 29 Oct 2018.
- 5.de Miguel Buckley R, Montejano R, Stella-Ascariz N, et al. New strategies of ARV: the road to simplification. Curr HIV/AIDS Rep. 2018;15(1):11–9.Google Scholar
- 8.European Medicines Agency. Juluca 50 mg/25 mg film-coated tablets: EU summary of product characteristics; 2018. http://www.ema.europa.eu. Accessed 29 Oct 2018.
- 9.ViiV Healthcare. JULUCA (dolutegravir and rilpivirine) tablets, for oral use: US prescribing information; 2017. https://www.fda.gov. Accessed 29 Oct 2018.
- 15.Orkin C, Khuong-Josses MA, Lutz T, et al. Safety and efficacy of DTG + RPV in the phase III SWORD-1 and SWORD-2 studies: 48-week subgroup analysis by baseline third agent class and geographic location [abstract no. P22]. HIV Med. 2018;19(Suppl 2):S28–9.Google Scholar
- 16.Walmsley S, Richmond GJ, Bredeek F, et al. SWORD-1 and SWORD-2: subgroup analysis of 48-week results by age, race and gender [abstract no. 1382 plus poster]. In: IDWeek; 2017.Google Scholar
- 17.Oglesby A, Punekar Y, Angelis K, et al. Patient reported outcomes after switching to a 2-drug regimen of dolutegravir + rilpivirine: results from the SWORD-1 and SWORD-2 studies [abstract no. BPD1/2 plus poster]. In: 16th European AIDS conference; 2017.Google Scholar
- 18.Aboud M, Orkin C, Podzamczer D, et al. Durable suppression 2 years after switch to DTG+RPV 2-drug regimen: SWORD 1 and 2 studies [abstract no. THPEB047]. In: 22nd international AIDS conference; 2018.Google Scholar
- 23.Diaz A, Casado JL, Dronda F, et al. Dolutegravir plus rilpivirine in suppressed heavily pre-treated HIV-infected patients [abstract no. TUPDB0106 plus poster]. In: 21st international AIDS conference; 2016.Google Scholar
- 24.Orkin C, Llibre J, Kahl L, et al. Renal, inflammatory and bone biomarkers following switch to the DTG + RPV 2-drug regimen: the SWORD-1 and SWORD-2 studies [abstract no. O37 plus oral presentation]. HIV Med. 2018;19(Suppl 2):S17.Google Scholar
- 25.US FDA. FDA drug safety communication: FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq); 2018. https://www.fda.gov. Accessed 29 Oct 2018.